Otonomy, Inc. Logo
Otonomy to Present at the J.P. Morgan Healthcare Conference
January 04, 2018 07:30 ET | Otonomy, Inc.
SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for diseases and disorders of the ear,...
Otonomy, Inc. Logo
Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 08, 2017 16:12 ET | Otonomy, Inc.
SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy, Inc. Logo
Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX™ in Patients with Ménière's Disease
November 08, 2017 16:05 ET | Otonomy, Inc.
Achieved primary endpoint (p value = 0.029)Company plans to meet with FDA to discuss results and clinical requirements for registrationManagement will review results during third quarter conference...
Otonomy, Inc. Logo
Otonomy to Report Third Quarter 2017 Financial Results and Provide Corporate Update
November 01, 2017 16:05 ET | Otonomy, Inc.
SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy, Inc. Logo
Otonomy Provides Business and Financial Update
September 13, 2017 07:30 ET | Otonomy, Inc.
Actions taken to reduce costs following suspension of OTIVIDEX™ developmentNon-commercial workforce reduced by one-thirdCurrent cash balance expected to fund company into 2020Review underway to...
Otonomy, Inc. Logo
Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update
August 03, 2017 16:12 ET | Otonomy, Inc.
SAN DIEGO, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy, Inc. Logo
Otonomy to Report Second Quarter 2017 Financial Results and Provide Corporate Update
July 27, 2017 07:30 ET | Otonomy, Inc.
SAN DIEGO, July 27, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy, Inc. Logo
Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO® in Acute Otitis Media with Tympanostomy Tubes
June 22, 2017 07:30 ET | Otonomy, Inc.
SAN DIEGO, June 22, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy, Inc. Logo
Otonomy to Host Key Opinion Leader Meeting for Investors on Ménière's Disease
June 20, 2017 07:30 ET | Otonomy, Inc.
SAN DIEGO, June 20, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy, Inc. Logo
Otonomy Announces OTIPRIO® Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual Meeting
May 12, 2017 07:30 ET | Otonomy, Inc.
SAN DIEGO, May 12, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...